

Rapid Case Review: Investigators Provide Perspectives on Actual Cases of Metastatic Bladder Cancer — Issue 4

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following management strategies is recommended by the faculty for a patient with metastatic urothelial bladder cancer (UBC) who after receiving 3 cycles of EV and pembrolizumab reports peripheral neuropathy that interferes with their ability to button clothing?**
 - Permanently discontinue EV
 - Continue EV at a reduced dose
 - Continue EV at a reduced dose and administer gabapentin
 - Withhold EV until the peripheral neuropathy is Grade 1 or lower, then resume treatment at the same dose
- 2. Which of the following regimens demonstrated a statistically significant progression-free survival benefit in comparison to chemotherapy as first-line therapy for HER2-expressing advanced UBC in a Phase III study?**
 - Trastuzumab/pertuzumab/nivolumab
 - Trastuzumab deruxtecan (T-DXd)/pembrolizumab
 - Disitamab vedotin/toripalimab
 - T-DXd/EV
- 3. Which of the following adverse events is commonly associated with EV?**
 - Constipation
 - Peripheral neuropathy
 - Atrial fibrillation
- 4. What was the approximate rate of pneumonitis reported in the DESTINY-PanTumor02 study evaluating T-DXd for HER2-positive advanced solid tumors?**
 - 2%
 - 10%
 - 20%